Jump to content

Fluocinolone acetonide: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m this doesn’t need a subsection #article-section-source-editor
Tags: Mobile edit Mobile app edit iOS app edit
infobox, description, refs, templates
Line 1: Line 1:
{{Short description|Corticosteroid anti-inflammatory drug}}
{{Short description|Corticosteroid anti-inflammatory drug}}
{{Use dmy dates|date=July 2024}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
Line 9: Line 11:


<!--Clinical data-->
<!--Clinical data-->
| tradename = Synalar, Iluvien, others
| tradename = Synalar, others
| Drugs.com = {{drugs.com|monograph|fluocinolone-topical}}<br />{{drugs.com|monograph|fluocinolone-acetonide-eent}}
| Drugs.com = {{drugs.com|monograph|fluocinolone-topical}}<br />{{drugs.com|monograph|fluocinolone-acetonide-eent}}
| pregnancy_AU = A
| pregnancy_AU = A
Line 60: Line 62:
}}
}}


'''Fluocinolone acetonide''' is a [[corticosteroid]] primarily used in [[dermatology]] to reduce skin inflammation and relieve itching.{{Citation needed|date=November 2019|reason=Please clarify which it is corticoid: gluco- or mineralo-}} It is a synthetic [[hydrocortisone]] derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City.<ref>{{cite journal | vauthors = Mills JS, Bowers A, Djerassi C, Ringold HJ | title = Steroids CXXXVII. Synthesis of a New Class of Potent Cortical Hormones. 6α,9α-Difluoro-16α-Hydroxyprednisolone and its Acetonide | journal = Journal of the American Chemical Society | volume = 80 | pages = 3399–3404 | date = 1960 | issue = 13 | doi = 10.1021/ja01498a041 }}</ref> Preparations containing it were first marketed under the name Synalar. A typical dosage strength used in dermatology is 0.01–0.025%. One such cream is sold under the brand name '''Flucort-N''' and includes the antibiotic [[neomycin]].
'''Fluocinolone acetonide''' is a fluorinated [[corticosteroid]] primarily used in [[dermatology]] to reduce skin inflammation and relieve itching.<ref name="AHFS" /> It is a synthetic [[hydrocortisone]] derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City.<ref>{{cite journal | vauthors = Mills JS, Bowers A, Djerassi C, Ringold HJ | title = Steroids CXXXVII. Synthesis of a New Class of Potent Cortical Hormones. 6α,9α-Difluoro-16α-Hydroxyprednisolone and its Acetonide | journal = Journal of the American Chemical Society | volume = 80 | pages = 3399–3404 | date = 1960 | issue = 13 | doi = 10.1021/ja01498a041 }}</ref> Preparations containing it were first marketed under the brand name '''Synalar'''.


Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated [[chondrogenesis]] of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.<ref name="pmid25753754">{{cite journal | vauthors = Hara ES, Ono M, Pham HT, Sonoyama W, Kubota S, Takigawa M, Matsumoto T, Young MF, Olsen BR, Kuboki T | display-authors = 6 | title = Fluocinolone Acetonide Is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration | journal = Journal of Bone and Mineral Research | volume = 30 | issue = 9 | pages = 1585–1596 | date = September 2015 | pmid = 25753754 | pmc = 5569386 | doi = 10.1002/jbmr.2502 }}</ref>
Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated [[chondrogenesis]] of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.<ref name="pmid25753754">{{cite journal | vauthors = Hara ES, Ono M, Pham HT, Sonoyama W, Kubota S, Takigawa M, Matsumoto T, Young MF, Olsen BR, Kuboki T | display-authors = 6 | title = Fluocinolone Acetonide Is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration | journal = Journal of Bone and Mineral Research | volume = 30 | issue = 9 | pages = 1585–1596 | date = September 2015 | pmid = 25753754 | pmc = 5569386 | doi = 10.1002/jbmr.2502 }}</ref>


Fluocinolone acetonide [[intravitreal implants]] have been used to treat non-infectious [[uveitis]]. A systematic review could not determine with any confidence whether fluocinolone acetonide implants are superior to standard of care treatment for uveitis.<ref>{{cite journal | vauthors = Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG | title = Corticosteroid implants for chronic non-infectious uveitis | journal = The Cochrane Database of Systematic Reviews | volume = 2023 | issue = 8 | pages = CD010469 | date = August 2023 | pmid = 37642198 | pmc = 10464657 | doi = 10.1002/14651858.CD010469.pub4 | pmc-embargo-date = August 29, 2024 }}</ref> A fluocinolone acetonide intravitreal implant with the brand name '''Iluvien''' is sold by biopharmaceutical company [[Alimera Sciences]] to treat [[diabetic macular edema]] (DME).<ref>{{cite web|url=https://www.healio.com/news/ophthalmology/20200702/realworld-study-shows-longterm-safety-efficacy-of-iluvien-in-dme |title=Real-world study shows long-term safety, efficacy of Iluvien in DME |website=Healio |date=2020-07-02 |access-date=2020-10-28}}</ref>
Fluocinolone acetonide [[intravitreal implants]] have been used to treat non-infectious [[uveitis]]. A systematic review could not determine with any confidence whether fluocinolone acetonide implants are superior to standard of care treatment for uveitis.<ref>{{cite journal | vauthors = Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG | title = Corticosteroid implants for chronic non-infectious uveitis | journal = The Cochrane Database of Systematic Reviews | volume = 2023 | issue = 8 | pages = CD010469 | date = August 2023 | pmid = 37642198 | pmc = 10464657 | doi = 10.1002/14651858.CD010469.pub4 | pmc-embargo-date = August 29, 2024 }}</ref> A fluocinolone acetonide intravitreal implant with the brand name Iluvien is sold by biopharmaceutical company [[Alimera Sciences]] to treat [[diabetic macular edema]].<ref>{{cite web|url=https://www.healio.com/news/ophthalmology/20200702/realworld-study-shows-longterm-safety-efficacy-of-iluvien-in-dme |title=Real-world study shows long-term safety, efficacy of Iluvien in DME |website=Healio |date=2020-07-02 |access-date=2020-10-28}}</ref>


<!-- Society and culture -->
<!-- Society and culture -->
Line 70: Line 72:


==Classification==
==Classification==
{{unreferenced section}}
Fluocinolone is a group V (0.025%) or group VI (0.01%) [[Topical steroid#USA system|corticosteroid under US classification]].
Fluocinolone is a group V (0.025%) or group VI (0.01%) [[Topical steroid#USA system|corticosteroid under US classification]].



==Brand names ==
==Brand names ==
* Yutiq<ref>{{cite web | title=Yutiq- fluocinolone acetonide implant | website=DailyMed | date=16 October 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f270cad8-ed82-4969-b785-831a1910bfa6 | access-date=25 December 2023}}</ref>
Fluocinolone acetonide is available under the brand names Flucort-N, Iluvien, Synalar, Yutiq,<ref>{{cite web | title=Yutiq- fluocinolone acetonide implant | website=DailyMed | date=16 October 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f270cad8-ed82-4969-b785-831a1910bfa6 | access-date=25 December 2023}}</ref> and others.<ref name="AHFS">{{cite web | title=Fluocinolone (Topical) Monograph for Professionals | website=Drugs.com | date=19 January 2024 | url=https://www.drugs.com/monograph/fluocinolone-topical.html | access-date=7 July 2024}}</ref><ref>{{cite web | title=Fluocinolone ophthalmic implant Uses, Side Effects & Warnings | website=Drugs.com | date=6 October 2023 | url=https://www.drugs.com/mtm/fluocinolone-ophthalmic-implant.html | access-date=7 July 2024}}</ref>


== References ==
== References ==
Line 84: Line 86:
{{Glucocorticoidics}}
{{Glucocorticoidics}}
{{Portal bar | Medicine}}
{{Portal bar | Medicine}}
{{Authority control}}


[[Category:Acetonides]]
[[Category:Acetonides]]
Line 94: Line 97:
[[Category:Otologicals]]
[[Category:Otologicals]]
[[Category:Substances discovered in the 1950s]]
[[Category:Substances discovered in the 1950s]]



{{cardiovascular-drug-stub}}
{{cardiovascular-drug-stub}}

Revision as of 07:20, 7 July 2024

Fluocinolone acetonide
Clinical data
Trade namesSynalar, others
AHFS/Drugs.comMonograph
Monograph
Pregnancy
category
  • AU: A
Routes of
administration		Topical, ophthalmic intravitreal injection
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismLiver, CYP3A4-mediated
Elimination half-life1.3 to 1.7 hours
Identifiers
  • (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.607 Edit this at Wikidata
Chemical and physical data
FormulaC24H30F2O6
Molar mass452.495 g·mol−1
3D model (JSmol)
  • O=C\1\C=C5/[C@@](/C=C/1)(C)[C@]2(F)[C@H]([C@H]3[C@](C[C@@H]2O)([C@@]4(OC(O[C@@H]4C3)(C)C)C(=O)CO)C)C[C@@H]5F
  • InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1 checkY
  • Key:FEBLZLNTKCEFIT-VSXGLTOVSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Fluocinolone acetonide is a fluorinated corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching.[2] It is a synthetic hydrocortisone derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City.[3] Preparations containing it were first marketed under the brand name Synalar.

Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.[4]

Fluocinolone acetonide intravitreal implants have been used to treat non-infectious uveitis. A systematic review could not determine with any confidence whether fluocinolone acetonide implants are superior to standard of care treatment for uveitis.[5] A fluocinolone acetonide intravitreal implant with the brand name Iluvien is sold by biopharmaceutical company Alimera Sciences to treat diabetic macular edema.[6]

It was approved for medical use in 1961.[7]

Classification

Fluocinolone is a group V (0.025%) or group VI (0.01%) corticosteroid under US classification.

Brand names

Fluocinolone acetonide is available under the brand names Flucort-N, Iluvien, Synalar, Yutiq,[8] and others.[2][9]

References

  1. ^ "Regulatory Decision Summary for Iluvien". Drug and Health Product Portal. Health Canada. 23 October 2014.
  2. ^ a b "Fluocinolone (Topical) Monograph for Professionals". Drugs.com. 19 January 2024. Retrieved 7 July 2024.
  3. ^ Mills JS, Bowers A, Djerassi C, Ringold HJ (1960). "Steroids CXXXVII. Synthesis of a New Class of Potent Cortical Hormones. 6α,9α-Difluoro-16α-Hydroxyprednisolone and its Acetonide". Journal of the American Chemical Society. 80 (13): 3399–3404. doi:10.1021/ja01498a041.
  4. ^ Hara ES, Ono M, Pham HT, Sonoyama W, Kubota S, Takigawa M, et al. (September 2015). "Fluocinolone Acetonide Is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration". Journal of Bone and Mineral Research. 30 (9): 1585–1596. doi:10.1002/jbmr.2502. PMC 5569386. PMID 25753754.{{cite journal}}: CS1 maint: overridden setting (link)
  5. ^ Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG (August 2023). "Corticosteroid implants for chronic non-infectious uveitis". The Cochrane Database of Systematic Reviews. 2023 (8): CD010469. doi:10.1002/14651858.CD010469.pub4. PMC 10464657. PMID 37642198.{{cite journal}}: CS1 maint: PMC embargo expired (link)
  6. ^ "Real-world study shows long-term safety, efficacy of Iluvien in DME". Healio. 2 July 2020. Retrieved 28 October 2020.
  7. ^ Fischer J, Ganellin CR, eds. (2006). "Tables of Structural and Functional Analogues: Systemic Hormonal Preparations". Analogue-based Drug Discovery. John Wiley & Sons. p. 485. ISBN 9783527607495.
  8. ^ "Yutiq- fluocinolone acetonide implant". DailyMed. 16 October 2023. Retrieved 25 December 2023.
  9. ^ "Fluocinolone ophthalmic implant Uses, Side Effects & Warnings". Drugs.com. 6 October 2023. Retrieved 7 July 2024.


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Stub icon

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

Stub icon

This ophthalmology article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Fluocinolone_acetonide&oldid=1233096870"